<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04532684</url>
  </required_header>
  <id_info>
    <org_study_id>ozgeilleez</org_study_id>
    <nct_id>NCT04532684</nct_id>
  </id_info>
  <brief_title>Comparison of the Efficacy of Duloxetine and Pregabalin in Patients With Knee Osteoarthritis With Mix Type Pain</brief_title>
  <official_title>Comparison of the Efficacy of Duloxetine and Pregabalin in Patients With Knee Osteoarthritis With Mix Type Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fatih Sultan Mehmet Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fatih Sultan Mehmet Training and Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Osteoarthritis (OA) is a common degenerative joint disorder associated with chronic pain at&#xD;
      older age.It is known that patients with osteoarthritis experience nociceptive and&#xD;
      neuropathic pain to varying degrees. Addition of molecules targeting neuropathic pain to&#xD;
      conventional therapy has been shown to improve treatment response in the management of&#xD;
      osteoarthritis.The aim of our study is to evaluate the effect of duloxetine and pregabalin on&#xD;
      pain, functional capacity, quality of life, depression, anxiety and sleep patterns in knee&#xD;
      osteoarthritis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 66 patients (aged 40-69) with knee osteoarthritis were randomized into two&#xD;
      treatment groups to receive either duloxetine 60mg/day or pregabalin 300mg/day. The patients&#xD;
      were evaluated before and one month after treatment and three months after treatment using&#xD;
      the visual analog scale (VAS-pain), Neuropathic Pain Diagnostic Questionnaire (DN4), Short&#xD;
      Form-36 (SF-36) Questionnaire, Western Ontario and McMaster University Osteoarthritis İndeks&#xD;
      (WOMAC), Beck Depression Scale (BDS), Beck Anxiety Akalası (BAS), Pittsburg Sleep Quality&#xD;
      Index (PSQI).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Actual">December 15, 2020</completion_date>
  <primary_completion_date type="Actual">July 15, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized prospective clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Double (Participant, Outcome Assesor)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Assessing Visual Analog Scale Score Change in Patients</measure>
    <time_frame>0.,4., and 12. weeks</time_frame>
    <description>All patients were asked to score the severity of their current knee pain on a 10-cm visual analogue scale (VAS).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neuropthic Pain Diagnostic Questionnaire (DN4)</measure>
    <time_frame>0.,4, and 12. weeks</time_frame>
    <description>There are 10 questions in the DN-4 including 7 questions related to pain quality and 3 questions that investigate the presence of tactile sensation, pinprick sensation, and allodynia. A total score 4/10 indicates neuropathic pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessing Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Score Change in Patients</measure>
    <time_frame>0., 4. and 12. weeks</time_frame>
    <description>The WOMAC consists of 24 questions that assess pain, stiffness, and problems with physical activities. The patient answers all questions on a 5-point Likert-type scale, and the total score ranges from 0 and 96.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessing Beck Depression Inventory Score Change in Patients</measure>
    <time_frame>0., 4. and 12. weeks</time_frame>
    <description>Symptoms of depression were evaluated by means of the Beck Depression Inventory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assesing Beck Anxiety Inventory Score Change in Patients</measure>
    <time_frame>0.,4.,and 12. weeks</time_frame>
    <description>Current anxiete state of patients was assessed by means of the Beck Anxiety Inventory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessing Pittsburgh Sleep Quality Index Score Change in Patients</measure>
    <time_frame>0.,4.,and 12. weeks</time_frame>
    <description>Sleep quality assessments were performed by means of the Pittsburgh Sleep Quality Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessing Short Form-36 (SF-36) Questionnaire Score Change in Patients</measure>
    <time_frame>0.,4.,and 12. weeks</time_frame>
    <description>The SF-36 has eight subscales and consists of a total of 36 questions. The subscales are vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health. A score of 0 is equivalent to maximum disability (poor quality of life), and a score of 100 is equivalent to no disability (good quality of life).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Duloxetine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>33 patients received 60 mg/day of duloxetine HCL orally for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregabalin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>33 patients received 300 mg/day of pregabalin orally for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <arm_group_label>Duloxetine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin</intervention_name>
    <arm_group_label>Pregabalin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 40-69&#xD;
&#xD;
          -  Diagnosed with knee osteoarthritis according to the American College of Rheumatology&#xD;
             (ACR) criteria&#xD;
&#xD;
          -  Grade 2-3 knee osteoarthritis according to Kellgren-Lawrence grading system&#xD;
&#xD;
          -  VAS-pain score: 4 and above&#xD;
&#xD;
          -  Neuropathic Pain Diagnostic Questionnaire (DN4) score: 4 and above&#xD;
&#xD;
          -  Body mass index value: 40 and below&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A history of trauma or surgical operation in the knee region&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Fibromyalgia&#xD;
&#xD;
          -  Inflammatory rheumatic disease&#xD;
&#xD;
          -  Central or peripheral neurological disorder&#xD;
&#xD;
          -  Severe cardiac, pulmonary, or malignant disease&#xD;
&#xD;
          -  Invasive treatment for knee last 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Özge Gülsüm İlleez, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fatih Sultan Mehmet Training and Research Hospital</affiliation>
  </overall_official>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 23, 2020</study_first_submitted>
  <study_first_submitted_qc>August 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2020</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Knee osteoartrhritis</keyword>
  <keyword>Duloxetine</keyword>
  <keyword>Pregabalin</keyword>
  <keyword>Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

